INTRODUCTION: The goal of the study was to determine the level of metabolic compensation expressed by glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose as determined after a standardized breakfast; further, to evaluate interrelationships between the studied parameters and postprandial glucose levels. METHODS: The study included 1055 patients with type 2 diabetes mellitus. Their fasting plasma glucose and postprandial glucose were measured before and after a standardized breakfast. Attending diabetologists completed a uniform questionnaire that included demographic data, type of antidiabetic treatment, duration of diabetes, latest glycosylated hemoglobin value, presence of dyslipidemia, and organic complications. RESULTS: Glycosylated hemoglobin < 53 mmol/mol was achieved in 363 (34.2%), postprandial glucose < 7.5 mmol/l in 211 (19.9%), and fasting plasma glucose < 6 mmol/l in 251 (23.7%) patients. Excellent metabolic compensation, indicated by all the above mentioned glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose values simultaneously, was achieved in only 71 (6.7%) patients. Comparable to fasting plasma glucose and postprandial glucose values, correlation with glycosylated hemoglobin levels is statistically significant; however, there is no difference at different glycosylated hemoglobin levels. There was a significant correlation between dyslipidemia and postprandial glycemia (p = 0.013). CONCLUSION: The objective of care for patients with diabetes mellitus is to improve their long-term metabolic compensation; to that end, both fasting plasma glucose and postprandial glucose deserve equal attention.

Department of Internal Medicine 2nd Faculty of Medicine Charles University Prague Czech Republic

Institute of Endocrinology Prague Czech Republic

Zobrazit více v PubMed

Caprnda M, Mesarosova D, Fabuel OP, et al. Glycemic variability and vascular complications in patients with type 2 diabetes mellitus. Folia Med. 2017;59(3):270–278. PubMed

Lin CC, Li CI, Yang SY, et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012;125(4):416.e9–416.e18. doi: 10.1016/j.amjmed.2011.07.027. PubMed DOI

DECODE Study Group, the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397–405. doi: 10.1001/archinte.161.3.397. PubMed DOI

Xu F, Zhao LH, Su JB, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6(1):139. doi: 10.1186/1758-5996-6-139. PubMed DOI PMC

Su G, Mi SH, Tao H, et al. Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care. 2013;36(4):1026–1032. doi: 10.2337/dc12-0925. PubMed DOI PMC

Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214–219. doi: 10.1161/01.CIR.0000134501.57864.66. PubMed DOI

Monnier L, Colette C. Targeting prandial hyperglycemia: how important is it and how best to do this? Curr Diab Rep. 2008;8(5):368–374. doi: 10.1007/s11892-008-0064-4. PubMed DOI

Monnier L, Colette C. Postprandial and basal hyperglycemia in type 2 diabetes: contributions to overall glucose exposure and diabetic complications. Diabetes Metab. 2015;41(6 Suppl 1):6S9–6S15. doi: 10.1016/S1262-3636(16)30003-9. PubMed DOI

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–442. doi: 10.1007/s00125-014-3460-0. PubMed DOI

American Diabetes Association Postprandial blood glucose. Diabetes Care. 2001;24:775–778. doi: 10.2337/diacare.24.4.775. PubMed DOI

Ceriello A, Colagiuri S, Gerich J, Tuomilehto J, Guideline Development Group Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis. 2008;18(4):S17–S33. doi: 10.1016/j.numecd.2008.01.012. PubMed DOI

Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels through-out the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001;24:2023–2029. doi: 10.2337/diacare.24.12.2023. PubMed DOI

Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care. 2007;30:263–269. doi: 10.2337/dc06-1612. PubMed DOI

Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164(19):2090–2095. doi: 10.1001/archinte.164.19.2090. PubMed DOI

Hanefeld M, Cagatay M, Petrowistch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–16. doi: 10.1016/S0195-668X(03)00468-8. PubMed DOI

Hanefeld M, Chiasson J-L, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschien T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;36:1073–1078. doi: 10.1161/01.STR.0000125864.01546.f2. PubMed DOI

NAVIGATOR Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463–1476. doi: 10.1056/NEJMoa1001122. PubMed DOI

Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2639–2646. doi: 10.1210/jc.2007-2000. PubMed DOI

Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813–819. doi: 10.1210/jc.2005-1005. PubMed DOI

Buscemi S, Re A, Batsis JA, et al. Glycemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in type 2 diabetes. Diabet Med. 2010;27(8):872–878. doi: 10.1111/j.1464-5491.2010.03059.x. PubMed DOI

Gradinaru D, Borsa C, Ionescu C, Margina D. Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J Proteomics. 2013;30(92):313–322. doi: 10.1016/j.jprot.2013.03.034. PubMed DOI

Mah E, Bruno RS. Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences. Nutr Res. 2012;32(10):727–740. doi: 10.1016/j.nutres.2012.08.002. PubMed DOI

Guidelines of Czech Society of Diabetes. http://www.diab.cz.

Monnier L, Colette C, Boniface H. Contribution of postprandial glucose to chronic hyperglycemia: from the “glucose triad” to the trilogy of “sevens”. Diabetes Metab. 2006;32(Spec No2):2S11–2S16. PubMed

Monnier L, Colette C, Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther. 2011;13(Suppl 1):S25–S32. PubMed

Woo V, Shestakova MV, Ørskov C, Ceriello A. Targets and tactics: the relative importance of HbA1c, fasting and postprandial plasma glucose levels to glycemic control in type 2 diabetes. Int J Clin Pract. 2008;62(12):1935–1942. doi: 10.1111/j.1742-1241.2008.01941.x. PubMed DOI

Aronoff SL. Rationale for treatment options for mealtime glucose control in patient with type 2 diabetes. Postgrad Med. 2017;129(2):231–241. doi: 10.1080/00325481.2017.1285191. PubMed DOI

Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265. doi: 10.2337/diacare.28.2.260. PubMed DOI

Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, Lispro Mixture-Glargine Study Group Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26(12):2034–2044. doi: 10.1016/j.clinthera.2004.12.015. PubMed DOI

Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycemic control in patients with type 2 diabetes. Diabet Med. 2005;22(4):374–381. doi: 10.1111/j.1464-5491.2005.01511.x. PubMed DOI

Ceriello A, Quagliaro L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25(8):1439–1443. doi: 10.2337/diacare.25.8.1439. PubMed DOI

Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med. 2004;21(2):171–175. doi: 10.1111/j.1464-5491.2004.01101.x. PubMed DOI

Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35(5):1073–1078. doi: 10.1161/01.STR.0000125864.01546.f2. PubMed DOI

Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol. 2007;27(11):2456–2462. doi: 10.1161/ATVBAHA.107.152835. PubMed DOI

Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227(2):349–354. doi: 10.1016/j.atherosclerosis.2012.12.018. PubMed DOI

Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–494. doi: 10.1001/jama.290.4.486. PubMed DOI

Dysglycemia and Abnormal Adiposity Drivers of Cardiometabolic-Based Chronic Disease in the Czech Population: Biological, Behavioral, and Cultural/Social Determinants of Health

Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study)